A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy (PiNACLE-H2H)

Lyell Immunopharma

Status and phase: Enrolling; Phase 3

Conditions: Lymphoma, B-Cell; Diffuse Large B Cell Lymphoma Refractory; Relapsed Non-Hodgkin Lymphoma; Large B-cell Lymphoma; Diffuse Large B Cell Lymphoma (DLBCL); Diffuse Large B Cell Lymphoma Relapsed; Non-Hodgkin Lymphoma Refractory/ Relapsed; Non-Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma

Treatments: Biological: axicabtagene ciloleucel; Biological: lisocabtagene maraleucel; Biological: rondecabtagene autoleucel

Study type: Interventional

Funder types: Industry

Identifiers

NCT07188558

LYL314-102

Details and patient eligibility

About

This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.

Full description

PiNACLE-H2H is a Phase 3 randomized controlled trial comparing the efficacy and safety of rondecabtagene autoleucel (ronde-cel, formerly known as LYL314) against the currently approved cluster of differentiation (CD)19 chimeric antigen receptor (CAR) T-cell therapies (axicabtagene ciloleucel [axi-cel] or lisocabtagene maraleucel [liso-cel]), in patients with aggressive LBCL that has relapsed or is refractory to first-line anti-CD20 antibody and anthracycline-containing chemotherapy.

Patients will be randomized (1:1) before leukapheresis to receive either:

• Ronde-cel; or
• Investigator's choice of axi-cel or liso-cel

Most patients who receive currently approved CD19-directed CAR T-cell therapies, including axi-cel and liso-cel, still experience progressive disease, often due to mechanisms such as CD19 antigen loss or T-cell exhaustion.

Ronde-cel is a novel, autologous, dual-targeting CD19/CD20 CAR T-cell product candidate enriched for CD62L-positive naïve and central memory T cells, which are associated with enhanced proliferation capacity and persistence. Ronde-cel is an "OR"-gated CAR construct that can fully activate upon recognition of either CD19 or CD20, aiming to improve durability of response despite antigen heterogeneity.

Approximately 400 participants will be enrolled. CAR T-cell therapy in both arms will be administered as a single intravenous infusion following fludarabine and cyclophosphamide lymphodepletion. Participants will be followed for 3 years for safety and efficacy, with long-term follow-up extending to 15 years.

Enrollment: 400 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

1. CAR T cell naïve and eligible to receive a CD19 CART-cell therapy

2. Histologically confirmed large B-cell lymphoma, including the following types defined by (WHO 2022) or International Consensus Classification (2022)

   • Diffuse large B-cell lymphoma (DLBCL)
   • Transformations of indolent B-cell lymphomas (excluding Richter's transformation)
   • DLBCL/High-grade B-cell lymphoma (HGBCL) with MYC and BCL2 rearrangements
   • High-grade B-cell lymphoma (HGBCL) not otherwise specified (HGBCL NOS)
   • Primary mediastinal large B-cell lymphoma (PMBCL)
   • Grade 3B follicular lymphoma/large cell follicular lymphoma (FL3B)

3. Relapsed or refractory disease after anti-CD20 antibody and anthracycline-containing first-line chemoimmunotherapy

4. Measurable disease by presence of [18F]-fluorodeoxyglucose PET/CT positive lesion during Screening per Lugano Criteria

5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

6. Adequate hematological, renal, hepatic, pulmonary, and cardiac function

Key Exclusion Criteria:

1. Patients ineligible to receive CD19 CAR T-cell therapy
2. Primary CNS lymphoma
3. Patients with primary cutaneous LBCL, human herpes virus-8 positive lymphoma, Burkitt lymphoma, T cell histiocyte-rich lymphoma, or transformation from chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter's transformation)
4. Patients with prior history of malignancy, other than aggressive relapsed or refractory LBCL, unless the patient has been free of the disease for ≥ 2 years
5. Patients with uncontrolled systemic fungal, bacterial, viral, or other infection (including tuberculosis) despite appropriate antibiotics or other treatment
6. Active autoimmune disease requiring ongoing systemic immunosuppressive therapy.

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

400 participants in 2 patient groups

Rondecabtagene autoleucel

Experimental group

Treatment:

Biological: rondecabtagene autoleucel

Investigator's Choice CD19

Active Comparator group

Description:

axicabtagene ciloleucel, lisocabtagene maraleucel

Treatment:

Biological: lisocabtagene maraleucel

Biological: axicabtagene ciloleucel